

# Conjugated Linoleic Acid Is a Preferential Substrate for Fatty Acid Nitration<sup>\*[5]</sup>

Received for publication, July 16, 2012, and in revised form, October 30, 2012. Published, JBC Papers in Press, November 9, 2012, DOI 10.1074/jbc.M112.401356

Gustavo Bonacci<sup>‡</sup>, Paul R. S. Baker<sup>‡</sup>, Sonia R. Salvatore<sup>‡</sup>, Darla Shores<sup>§</sup>, Nicholas K. H. Khoo<sup>‡</sup>, Jeffrey R. Koenitzer<sup>‡</sup>, Dario A. Vitturi<sup>‡</sup>, Steven R. Woodcock<sup>‡</sup>, Franca Golin-Bisello<sup>‡</sup>, Marsha P. Cole<sup>‡</sup>, Simon Watkins<sup>¶</sup>, Claudette St. Croix<sup>¶</sup>, Carlos I. Batthyany<sup>||</sup>, Bruce A. Freeman<sup>†1</sup>, and Francisco J. Schopfer<sup>‡2</sup>

From the Departments of <sup>‡</sup>Pharmacology and Chemical Biology, <sup>§</sup>Pediatrics, <sup>¶</sup>Cell Biology and Physiology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261 and the <sup>||</sup>Pasteur Institute, Montevideo 11400, Uruguay

**Background:** Nitroalkene fatty acids are electrophilic cell metabolites that mediate anti-inflammatory signaling actions.

**Results:** Conjugated linoleic acid is the preferential unsaturated fatty acid substrate for nitration reactions during oxidative inflammatory conditions and digestion.

**Conclusion:** Nitro-fatty acid formation *in vivo* occurs during metabolic and inflammatory reactions and modulates cell signaling.

**Significance:** Nitro-conjugated linoleic acid transduces signaling actions of nitric oxide, nitrite, and conjugated linoleic acid.

The oxidation and nitration of unsaturated fatty acids by oxides of nitrogen yield electrophilic derivatives that can modulate protein function via post-translational protein modifications. The biological mechanisms accounting for fatty acid nitration and the specific structural characteristics of products remain to be defined. Herein, conjugated linoleic acid (CLA) is identified as the primary endogenous substrate for fatty acid nitration *in vitro* and *in vivo*, yielding up to 10<sup>5</sup> greater extent of nitration products as compared with bis-allylic linoleic acid. Multiple enzymatic and cellular mechanisms account for CLA nitration, including reactions catalyzed by mitochondria, activated macrophages, and gastric acidification. Nitroalkene derivatives of CLA and their metabolites are detected in the plasma of healthy humans and are increased in tissues undergoing episodes of ischemia reperfusion. Dietary CLA and nitrite supplementation in rodents elevates NO<sub>2</sub>-CLA levels in plasma, urine, and tissues, which in turn induces heme oxygenase-1 (HO-1) expression in the colonic epithelium. These results affirm that metabolic and inflammatory reactions yield electrophilic products that can modulate adaptive cell signaling mechanisms.

Products of oxidative inflammatory reactions mediate both the progression and resolution of inflammation (1). Notably, unsaturated fatty acids can induce adaptive cell signaling responses and modulate the resolution of inflammation by the redox-dependent formation and secondary reactions of

noneicosanoid oxo and nitroalkene derivatives (2). These signaling actions are transduced *in vitro* and *in vivo* via the post-translational modification of functionally significant nucleophilic amino acids of susceptible transcription factors and enzymes (3, 4).

Multiple clinical trials support that the increased dietary intake of  $\omega$ -3 unsaturated fatty acids promotes a broad range of physiological benefits (5). The beneficial actions of conjugated diene-containing fatty acids in both animal models and clinical studies have also been reported. The predominant conjugated diene species found clinically are octadeca-(9Z,11E)-dienoic and octadeca-(10E,12Z)-dienoic acid, referred to herein as conjugated linoleic acid (CLA)<sup>3</sup> (6). Notably, CLA is distinct from octadeca-(9Z,12Z)-dienoic acid (linoleic acid, LA) by having a conjugated rather than methylene-interrupted diene. Oxidative inflammatory reactions also give rise to elevated levels of conjugated diene-containing lipids that are generated from bis-allylic dienes following hydrogen abstraction (7). The conjugation of double bonds promotes radical addition reactions to both CLA and other conjugated diene-containing species (8).

Both  $\omega$ -3 fatty acids and CLA have been proposed to exert anti-inflammatory actions by serving as endogenous peroxisome proliferator-activated receptor (PPAR) ligands and inhibitors of nuclear factor- $\kappa$ B (NF- $\kappa$ B)-dependent cytokine expression (9, 10). Notably, electrophilic derivatives of these unsaturated fatty acids (*i.e.* nitroalkene and  $\alpha,\beta$ -unsaturated

\* This work was supported, in whole or in part, by National Institutes of Health Grants R01-HL058115, R01-HL64937, P30-DK072506, P01-HL103455 (to B. A. F.), and R01 AT006822-01 (to F. J. S.). B. A. F. and F. J. S. acknowledge financial interest in Complexa, Inc.

[5] This article contains supplemental Figs. 1–7 and Tables 1 and 2.

<sup>1</sup> To whom correspondence may be addressed: Dept. of Pharmacology and Chemical Biology, Thomas E. Starzl Biomedical Science Tower E1340, 200 Lothrop St., University of Pittsburgh, Pittsburgh, PA 15213. Tel.: 412-648-9319; Fax: 412-648-2229; E-mail: freerad@pitt.edu.

<sup>2</sup> To whom correspondence may be addressed: Dept. of Pharmacology and Chemical Biology, Thomas E. Starzl Biomedical Science Tower E1340, 200 Lothrop St., University of Pittsburgh, Pittsburgh, PA 15213. Tel.: 412-648-9319; Fax: 412-648-2229; E-mail: fjs2@pitt.edu.

<sup>3</sup> The abbreviations used are: CLA, octadeca-(9Z,11E)-dienoic acid; CID, collision-induced dissociation;  $\beta$ -ME,  $\beta$ -mercaptoethanol; DTPA, diethylenetriaminepentaacetic acid; <sup>•</sup>NO, nitric oxide; <sup>•</sup>NO<sub>2</sub>, nitrogen dioxide; HNO<sub>2</sub>, nitrous acid; OA, oleic acid; LA, linoleic acid; NO<sub>2</sub>-FA, nitrated fatty acid; NO<sub>2</sub>-OA, nitro-oleic acid; NO<sub>2</sub>-LA, nitro-linoleic acid; NO<sub>2</sub>-CLA (equimolar mixture of 9-NO<sub>2</sub>-CLA [9-nitro-octadeca-9,11-dienoic acid] and 12-NO<sub>2</sub>-CLA [12-nitro-octadeca-9,11-dienoic acid]); 10-NO<sub>2</sub>-CLA [10-nitro-octadeca-10,12-dienoic acid]; 13-NO<sub>2</sub>-CLA [13-nitro-octadeca-10,12-dienoic acid]; NO<sub>2</sub>-oxo-OA, nitro-oxo-octadec-10-enoic acid; NO<sub>2</sub>-OH-OA, nitro-hydroxyoctadec-10-enoic acid; PPAR, peroxisome proliferator-activated receptor; MPO, myeloperoxidase; MRM, multiple reaction monitoring. The designations "9-NO<sub>2</sub>-" and "12-NO<sub>2</sub>-" CLA are used herein to describe position of the nitro group in conjugated dienes and do not refer to IUPAC nomenclature.

carbonyl species) are critical proximal mediators of these signaling actions, because electrophilic fatty acids are orders of magnitude more potent than native unsaturated fatty acids in modulating these and other key tissue-protective and adaptive signaling mechanisms (2, 3, 11). Electrophilic lipids mediate signaling responses via Michael addition, inducing post-translational protein modifications (2). These often reversible reactions can be modulated by relative concentrations of competing tissue nucleophiles such as GSH and H<sub>2</sub>S (12). In human coronary artery endothelium for example, fatty acid nitroalkenes significantly influence the expression of ~400 metabolic and anti-inflammatory-related genes (13). Specific cellular nitroalkylation targets include functionally significant thiol residues in the transcriptional regulatory proteins PPAR $\gamma$  (14), Keap1/Nrf2 (Kelch-like ECH-associated protein 1 (Keap1)/regulator of nuclear factor (erythroid-derived-2)-like 2 (Nrf2)) (15), heat shock factor-1 (HSF-1), and NF- $\kappa$ B (4).

In model systems, unsaturated fatty acid nitration is induced by oxides of nitrogen (NO<sub>x</sub>) such as nitrogen dioxide ( $\text{NO}_2$ ), nitrite ( $\text{NO}_2^-$ ), and peroxyxynitrite ( $\text{ONOO}^-$ ), all products of nitric oxide ( $\text{NO}$ ) oxidation or the dietary consumption and further reactions of  $\text{NO}_2^-$  and nitrate ( $\text{NO}_3^-$ ) (16). Nitric oxide does not directly nitrate protein or lipids, rather its oxidation to the proximal nitrating species  $\text{NO}_2$  is essential. Multiple mechanisms can account for endogenous  $\text{NO}_2$  generation, including the following: (a) oxidation of  $\text{NO}$  by oxygen ( $\text{O}_2$ ); (b) reaction of  $\text{NO}$  with superoxide ( $\text{O}_2^-$ ) to yield  $\text{ONOO}^-$ ; (c) the one-electron oxidation of  $\text{NO}_2^-$  by heme peroxidases (*i.e.* myeloperoxidase (MPO) and eosinophil peroxidase); and (d) the acid-catalyzed protonation of  $\text{NO}_2^-$  to nitrous acid ( $\text{HNO}_2$ ). These oxidizing and nitrating species are produced both basally and at increased rates during inflammation and metabolic stress.

The mechanisms underlying biological fatty acid nitration and the structural characteristics of products require additional characterization (17–19). Importantly,  $\text{NO}_2^-$ -supplemented diets are associated with a variety of beneficial anti-inflammatory and metabolic actions, including the regulation of mitochondrial function, adipogenesis, oxygen delivery to tissues, and blood pressure (20). Although these events can in part be attributed to the generation of  $\text{NO}$ , salutary responses to  $\text{NO}_2^-$ -derived oxides of nitrogen may also be transduced by the concomitant generation of electrophilic nitro-fatty acids ( $\text{NO}_2$ -FA).

Herein, we report the formation of previously undescribed endogenous  $\text{NO}_2$ -FA species, the nitro derivatives of CLA (9- and 12-nitro-octadeca-(9,11)-dienoic acid), termed  $\text{NO}_2$ -CLA, and we show their presence in the plasma of healthy individuals. CLA is the preferential endogenous substrate for the fatty acid nitration reactions promoted by  $\text{NO}$  and  $\text{NO}_2^-$ . Moreover, rodents supplemented with CLA and the stable isotope [ $^{15}\text{N}$ ] $\text{O}_2^-$  display elevated tissue, plasma, and urine content of [ $^{15}\text{N}$ ] $\text{O}_2$ -CLA. These electrophilic nitroalkene derivatives, formed endogenously during inflammatory conditions and gastric acidification, mediate transcriptional regulatory responses that can account for a component of the tissue-protective and anti-inflammatory actions attributed to  $\text{NO}$ ,  $\text{NO}_2^-$ , and CLA (21–23).

## EXPERIMENTAL PROCEDURES

**Materials**—All chemicals and fatty acids were purchased from Sigma and Nu-Chek Prep, Inc. (Elysian, MN), respectively. Internal standards ( $^{13}\text{C}_{18}$ ] $\text{NO}_2$ -OA and [ $^{13}\text{C}_{18}$ ] $\text{NO}_2$ -LA) were synthesized as described previously (18, 25). For animal studies, male Sprague-Dawley rats (Harlan Lab, Indianapolis, IN), 200–250 g body mass, and C57Bl6 mice were housed in accordance with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (publication number 85-23, revised 1996), and all procedures were approved by the Institutional Animal Care and Use Committee of the University of Pittsburgh (protocol numbers 0911852, 0901770B-4, and 0905750B-7).

**Lipid Extraction from Urine**—In rodent studies, urine was collected over a 24-h period by capture in a metabolic cage. Lipids were extracted using C-18 solid phase extraction (SPE) columns conditioned with 100% MeOH, followed by equilibration with 5% MeOH/H<sub>2</sub>O. Urine containing 5% MeOH and 3.0 ng/ml internal standard (equilibrated at 4 °C for 30 min prior to extraction) was loaded and sequentially washed with 2 column volumes each of H<sub>2</sub>O, 5% MeOH, and 50% MeOH. Lipids were eluted with 3 ml of MeOH, dried, and dissolved in MeOH for quantitative HPLC-MS/MS analysis.

**Mass Spectrometry**—Quantification and structural analysis of nitrated species were conducted by high performance liquid chromatography-electrospray ionization tandem mass spectrometry (HPLC-ESI-MS/MS) using a triple quadrupole mass spectrometer in positive and negative ion mode (API 5000 and API QTrap 4000, Applied Biosystems, Framingham, MA) and a high resolution hybrid mass spectrometer (Velos Orbitrap, ThermoScientific).  $\text{NO}_2$ -FA were separated with a C18 reversed phase column (2 × 150 mm, 3  $\mu\text{m}$ , Phenomenex, Torrance, CA) using a water/acetonitrile solvent system containing 0.1% acetic acid. Reactivity toward  $\beta$ -ME and the Dess Martin reaction were used to characterize electrophilicity and the presence of hydroxy groups, respectively (26).

**$\text{NO}_2$ -FA Formation by Mitochondria and Cardiac Tissue**—Rat liver mitochondria from male Sprague-Dawley rats were isolated as described previously (27). For all reactions, 2 mg of liver mitochondrial protein was incubated in the presence or absence of  $\text{NaNO}_2$  or  $\text{Na}^{15}\text{N}]\text{O}_2$  (0–1000  $\mu\text{M}$ ) for 0–4 h at 37 °C with or without fatty acid supplementation. Similar results were obtained for heart mitochondria. The ischemia/reperfusion data were obtained upon MS analysis of archived murine cardiac tissue that was subjected to 30 min of ligation of the coronary artery and 30 min of reperfusion as described previously (17).

**CLA Nitration by MPO and  $\text{ONOO}^-$** —(9Z,11E)-CLA, (10E,12Z)-CLA, and LA (1  $\mu\text{M}$ ) were subjected to nitration by MPO (50 ng) in 50 mM sodium phosphate, pH 7.2, 100  $\mu\text{M}$  DTPA, in the presence of H<sub>2</sub>O<sub>2</sub> (100  $\mu\text{M}$ ),  $\text{NaNO}_2$  (100  $\mu\text{M}$ ) for 0–2 h at 37 °C, followed by addition of internal standard ( $^{13}\text{C}_{18}$ ] $\text{NO}_2$ -LA) prior to extraction.  $\text{ONOO}^-$  (0–20  $\mu\text{M}$ ,  $\epsilon_{302\text{ nm}} = 1.67\text{ mm}^{-1}\text{ cm}^{-1}$ ) was added to CLA or LA (10  $\mu\text{M}$ ) in 50 mM potassium phosphate, pH 7.2, containing 100  $\mu\text{M}$  DTPA. Reverse order additional studies were carried out by adding

ONOO<sup>-</sup> to buffers for 30 s to promote decomposition prior to CLA or LA addition.

**CLA Nitration by Activated Macrophages**—RAW 264.7 macrophages were activated with LPS (100 ng/ml) and INF $\gamma$  (200 units/ml) for 12 h; media were replaced with HBSS containing 10  $\mu$ M CLA or LA for 6 h in the presence or absence of L-NAME. Media NO<sub>2</sub><sup>-</sup> and NO<sub>2</sub>-FA determinations were performed using a Sievers nitric oxide analyzer 280i (General Electric, Boulder, CO) and mass spectrometry, respectively.

**Fatty Acid Nitration by <sup>15</sup>N<sub>2</sub> Gas**—(9Z,11E)-CLA or (9Z,12Z)-LA (100  $\mu$ M) in 50 mM sodium phosphate, pH 6.0, 100  $\mu$ M DTPA was exposed to 5.6 ppm <sup>15</sup>N<sub>2</sub> gas flowing over the headspace at 690 ml/min for 60 min in the dark using N<sub>2</sub> (~10 mm Hg residual O<sub>2</sub> was measured using a blood gas analyzer) or air (20.9% oxygen) as the carrier gas.

**Detection of NO<sub>2</sub>-CLA in Healthy Human Plasma**—Lipids from human plasma (1.5 ml) (University of Pittsburgh IRB approval PRO07110032) were extracted using 3.5 ml of hexane, propan-2-ol, 1 M formic acid (30:20:2, v/v/v) in the presence of 1 mM 1,3-hexadiene (added to quench possible <sup>15</sup>N<sub>2</sub> radicals) in a two-step solvent extraction with hexane. Quantification was performed by LC-ESI-MS/MS using [<sup>15</sup>N]O<sub>2</sub>-CLA as an internal standard. Artifacts during extraction procedures was controlled in parallel by adding a large excess (100  $\mu$ M) of Na[<sup>15</sup>N]O<sub>2</sub> and 1 mM 1,3-hexadiene to plasma and following the formation of [<sup>15</sup>N]O<sub>2</sub>-CLA in the presence of [<sup>13</sup>C<sub>18</sub>]NO<sub>2</sub>-LA as an internal standard.

**Gastric Generation of NO<sub>2</sub>-CLA**—Mice fasted overnight were intraperitoneally injected with pentagastrin (5 mg/kg) 60 min prior to oral gavage with 100 nmol each of CLA and Na[<sup>15</sup>N]O<sub>2</sub> (0.23 mg/kg) in 100  $\mu$ l of PEG 400. Typical dietary consumption of NO<sub>2</sub><sup>-</sup> by humans (based on an average weight of 60 kg) is 0.33 mg/kg. Other groups of mice were given higher CLA and Na[<sup>15</sup>N]O<sub>2</sub> doses (100  $\mu$ mol and 10  $\mu$ mol, respectively, in 100  $\mu$ l of PEG 400), which equates to 23 mg of NO<sub>2</sub><sup>-</sup>/kg. Animals were euthanized at various times, and stomach, small intestine, and colon were harvested and frozen in liquid nitrogen, pulverized, and lipids extracted for MS analysis.

Similar experiments were performed with rats treated via oral gavage every 24 h for 4 days with 100  $\mu$ mol each of CLA and Na[<sup>15</sup>N]O<sub>2</sub> in 100  $\mu$ l of PEG 400. Control rats included gavage with vehicle, 100  $\mu$ mol of CLA, or 100  $\mu$ mol of NO<sub>2</sub><sup>-</sup>. During the final 24 h of treatment, before euthanasia, animals were housed in metabolic cages, fasted overnight, and intraperitoneally injected with pentagastrin (5 mg/kg) 60 min prior to a final oral gavage with 100  $\mu$ mol each of CLA and Na[<sup>15</sup>N]O<sub>2</sub> (28). At various times, tissues and plasma were harvested and lipids extracted as described previously using [<sup>13</sup>C<sub>18</sub>]NO<sub>2</sub>-LA as an internal standard and analyzed by HPLC-MS/MS. NO<sub>2</sub>-CLA levels (<sup>14</sup>N and <sup>15</sup>N) in urine obtained from the cages were collected and quantified.

**HO-1 Immunocytochemistry**—The colon from vehicle, CLA, NO<sub>2</sub><sup>-</sup>, and CLA + NO<sub>2</sub><sup>-</sup>-treated rats was divided to provide tissue for both lipid and immunocytochemical analyses. In addition, a group of rats received NO<sub>2</sub>-CLA by gavage (770 nmol) 8 h prior to colon dissection. The proximal colon was cut into 2–3-cm segments and fixed. Sections (5  $\mu$ m) were mounted on slides and processed for immunocytochemical

analyses. HO-1 was detected with a specific antibody (rabbit, Abcam) and visualized with anti-rabbit IgG labeled with Cy3 (Jackson ImmunoResearch). Actin distribution was detected with Alexa488-labeled phalloidin (Invitrogen) and the nuclei with Hoechst dye (Invitrogen). Images were collected with an Olympus FV1000 confocal microscope using a  $\times$ 20 oil immersion objective. All settings (laser power, photomultiplier tube voltage, and offset) were kept constant for the collection of all images.

**HO-1 Expression in RAW 264.7 Macrophages**—RAW 264.7 cells were grown to 90% confluence on 6-well plates and incubated with 1–5  $\mu$ M [<sup>15</sup>N]O<sub>2</sub>-CLA, the specific isomer 9-NO<sub>2</sub>-CLA, NO<sub>2</sub>-LA, and 5  $\mu$ M CLA and LA as fatty acid controls for 12 h. Protein samples were harvested, homogenized in lysis buffer, resolved by SDS-PAGE, and transferred to PVDF membranes (Bio-Rad).

**Statistics**—A one-way analysis of variance test with post hoc Tukey test was used to analyze data.

## RESULTS

**Mitochondrial Fatty Acid Nitration**—Isolated rat liver mitochondria were incubated with NO<sub>2</sub><sup>-</sup> at pH ranges reflective of tissue ischemia (29). HPLC-MS/MS precursor ion scanning of lipid extracts revealed the loss of an organic nitro group as NO<sub>2</sub><sup>-</sup> (*m/z* 46). This sentinel fragment ion for nitrated species was predominantly from parent ions with *m/z* 324.2. Two peaks (36.3 and 37.4 min) were detected by following the multiple reaction monitoring (MRM) transition 324.2/46 and displayed the same retention time as nitrated fatty acids generated in cardiac tissue homogenates after rodent hearts were subjected to focal myocardial ischemia-reperfusion (I/R) (Fig. 1*a*) (17). Importantly, these peaks displayed longer retention times when resolved on a C18 reversed phase column than the [<sup>13</sup>C<sub>18</sub>]NO<sub>2</sub>-LA used as an internal standard. This standard consisted of the 9-,10-,12-, and 13-NO<sub>2</sub> positional isomers of [<sup>13</sup>C<sub>18</sub>]NO<sub>2</sub>-LA (Fig. 1*a*). Product ions obtained upon MS/MS fragmentation of mitochondrially generated NO<sub>2</sub>-FA (*m/z* 324.2 and 325.2, for species having -NO<sub>2</sub> and -[<sup>15</sup>N]O<sub>2</sub> groups, respectively), displayed the common losses of H<sub>2</sub>O and the distinctive anionic and neutral losses of NO<sub>2</sub><sup>-</sup> and HNO<sub>2</sub>, both indicative of fatty acid nitroalkene derivatives (Fig. 1*b*) (30). The mitochondrial generation of these species was dependent on both pH and NO<sub>2</sub><sup>-</sup> concentrations, with a 10-fold increase in fatty acid nitration at pH 6.0 (1.1 pg of NO<sub>2</sub>-FA/mg of mitochondrial protein), compared with pH 7.0 (0.1 pg of NO<sub>2</sub>-FA/mg of mitochondrial protein). This is consistent with the reactions of secondary oxides of nitrogen formed upon NO<sub>2</sub><sup>-</sup> protonation (Fig. 1*c*). This supports that metabolic and inflammatory conditions having increased NO<sub>2</sub><sup>-</sup> levels and decreased pH will catalyze mitochondrial lipid nitration.

**Mass Spectrometric Characterization of Mitochondrial NO<sub>2</sub>-FA**—To gain further insight into the structural characteristics of the nitrated fatty acid species having longer HPLC elution times than the synthetic standard, MS<sup>2</sup> analysis in the positive ion mode was performed. Upon collision induced dissociation (CID), lithium adducts of fatty acid nitroalkenes generate specific product ions predictive of the overall nitroalkene position in the parent ion (31). The MS<sup>2</sup> spectrum of lithium

## Fatty Acid Nitration *in Vitro* and *in Vivo*




FIGURE 1. **Nitrite induces mitochondrial formation of NO<sub>2</sub>-FA.** Mitochondria were incubated for 2 h with NO<sub>2</sub><sup>-</sup> (0.2–1.0 mM) in phosphate buffer (50 mM, pH 6). *a*, chromatogram showing nitration of 18:2 fatty acids in mitochondria by [<sup>15</sup>N]O<sub>2</sub><sup>-</sup> or NO<sub>2</sub><sup>-</sup>, cardiac tissue from mice subjected to focal myocardial I/R and [<sup>13</sup>C<sub>18</sub>]NO<sub>2</sub>-LA internal standard, respectively. Product ions of *m/z* 46 (NO<sub>2</sub><sup>-</sup>) and *m/z* 47 ([<sup>15</sup>N]O<sub>2</sub><sup>-</sup>) were followed upon fragmentation of ions *m/z* 324.2 and 325.2, respectively. *b*, MS-MS spectra of mitochondrial NO<sub>2</sub>-FA showing characteristic losses of H<sub>2</sub>O and NO<sub>2</sub><sup>-</sup> derived from organic nitro groups. *c*, NO<sub>2</sub><sup>-</sup> and pH dependence of mitochondrial fatty acid formation (followed as 324.2/46 MRM transition). *ND*, not detected. Results represent the mean of three independent experiments ± S.D.

adducts ([M + Li]<sup>+</sup>) of mitochondrially induced fatty acid nitration products (*m/z* 332.2, chromatographic peaks at 36.3 and 37.4 min) showed unique product ions with *m/z* 205.2 (RT 36.3 min) and *m/z* 192.2 (RT 37.4 min) (supplemental Fig. 1*a*). In contrast to the ion fragmentation of mitochondrial fatty acid nitration products, synthetic bis-allylic NO<sub>2</sub>-LA presented product ions with *m/z* 219.1 (34.6 min) and *m/z* 192.2 (35.8 min) (supplemental Table 1). The differences in the elution time between synthetic standard and mitochondrially derived fatty acid nitration products, along with the appearance of the 14 atomic mass units shift in product ion fragments upon CID (*m/z* 219.1 versus 205.1), indicated that the NO<sub>2</sub> group of mitochondrial nitroalkenes is placed at positions C-9 or C-12, with unsaturations at C-9 and C-11, respectively (supplemental Fig. 1*b*). To confirm this proposed isomeric structure, negative ion ESI-MS/MS product ions were evaluated using high resolution mass spectrometry (30). The atomic composition of the parent ions formed by mitochondria were C<sub>18</sub>H<sub>30</sub>NO<sub>4</sub><sup>-</sup> (theoretical *m/z* 324.2180, measured *m/z* 324.2182 (0.52 ppm)). CID induced gas-phase fragmentation of mitochondrially nitrated fatty acids, confirmed by high accuracy mass determinations at the 2 ppm level, revealed four characteristic product ions (*m/z* 157.1 (*a*), 171.1 (*b*), 195.1 (*d*), and 213.1 (*c*)) for the peak at RT for 36.5 min and three product ions (*m/z* 168.1 (*e*), 210.2 (*f*), and 224.2 (*g*)) for the peak at RT for 37.5 min (Fig. 2, *a* and *b*). These distinctive product ions were indicative of fragments derived from parent ions containing a nitro group at position C-12 or C-9 (Fig. 2*a* and supplemental Table 2), confirming the structural determinations from Li<sup>+</sup> adduct analysis. Further struc-

tural confirmation of mitochondrial NO<sub>2</sub>-FA was obtained by comparing HPLC elution and MS/MS fragmentation characteristics of products generated by acidic nitration of pure (9,11)- or (10,12)-CLA and synthetic NO<sub>2</sub>-LA. These results confirmed that the double bonds were present on carbons C-9 and C-11, consistent with the nitration of conjugated linoleic acid rather than bis-allylic LA, which contains methylene-interrupted double bonds (supplemental Tables 1 and 2). The formation of 13-NO<sub>2</sub>-CLA and 10-NO<sub>2</sub>-CLA, minor nitration products of the less abundant mitochondrial pool of (10*E*,12*Z*)-CLA was also detected by CID analysis in positive (supplemental Fig. 1, *c* and *d*) and negative mode (supplemental Fig. 2, *a* and *b*). Production analysis of these isobaric species eluting at RT of 36.25 and 36.59 min gave specific transitions at *m/z* 171, 185, 209, and 227 (13-NO<sub>2</sub>-CLA) and 182, 224, and 238 (10-NO<sub>2</sub>-CLA), respectively, consistent with their predicted fragmentation (supplemental Fig. 2, *a* and *b*). These results affirm that nitration of (9,11)-CLA in mitochondria prevails over the less abundant (10,12)-CLA. Final structural confirmation came from the synthesis and purification of the 9- and 12-[<sup>15</sup>N]O<sub>2</sub>-CLA isomer mixture, with molecular structures confirmed by MS and <sup>1</sup>H NMR analysis (Fig. 5*a* and supplemental Fig. 3). Finally, the *de novo* synthesis of the specific isomer 9-NO<sub>2</sub>-CLA (to be reported separately) provided a standard for confirming the identification of the nitrated fatty acids detected in mitochondria (supplemental Fig. 2*c*).

**CLA Is the Substrate for Mitochondrially Induced Fatty Acid Nitration**—To further define fatty acid substrate selectivity for nitration, isolated mitochondria were supplemented with dif-




FIGURE 2. **Structural analysis of NO<sub>2</sub>-FA by collision-induced dissociation in the negative ion mode.** *a*, MS/MS spectra of ions with  $m/z$  324.2 (RT for 36.3 and 37.4 min) obtained from mitochondria exposed to NO<sub>2</sub>. Specific product ions were determined at a 1 ppm level for 12-NO<sub>2</sub>-CLA ( $m/z$  157.08 (*a*), 171.10 (*b*), 195.10 (*d*), and 213.11 (*c*)) and for 9-NO<sub>2</sub>-CLA ( $m/z$  168.10 (*e*), 210.11 (*f*), and 224.11 (*g*)). *b*, elution profile of NO<sub>2</sub>-CLA. MRM chromatograms of mitochondrial lipid extracts and CLA acidic nitration (*a*–*g*), analyzed by LC-ESI-MS/MS in the negative ion mode using specific transitions for NO<sub>2</sub>-CLA isomers, were determined in *a*.

ferent free fatty acids and NO<sub>2</sub><sup>-</sup>. The addition of both oleic acid (OA) and LA (1 μM each) did not impact the extent of fatty acid nitration and did not increase yields of nitrated products. Supplementation with CLA (1 μM) induced ~26-fold increase in NO<sub>2</sub>-CLA generation (Fig. 3*a*). NO<sub>2</sub>-CLA formation was time-, pH-, and [NO<sub>2</sub><sup>-</sup>]-dependent and correlates with decreased mitochondrial levels of free CLA (Fig. 3*b*). CLA was quantified by derivatization with 4-phenyl-1,2,4 triazoline-3,5-dione and HPLC-MS/MS analysis against standards (supplemental Fig. 4). This analysis revealed that CLA is present in mitochondrial membranes and is a preferential substrate for nitration reactions.

**Nitration of CLA by Macrophages**—Nitration of free and protein-associated tyrosine is a hallmark of oxidative inflammatory reactions stemming from <sup>•</sup>NO and NO<sub>2</sub><sup>-</sup> (32); thus, macrophage-induced CLA nitration was evaluated in this context. Activation of RAW 264.7 mouse macrophages with LPS/INFγ in the presence of (9*Z*,11*E*)-CLA yielded both 9-NO<sub>2</sub>-CLA and 12-NO<sub>2</sub>-CLA. These products co-eluted with 9- and 12-[<sup>15</sup>N]O<sub>2</sub>-CLA internal standards and yielded characteristic product ions (Fig. 3*c*). No additional nitration products were detected upon LA supplementation, further affirming the susceptibility of CLA to nitration. Addition of the NOS inhibitor L-NAME decreased macrophage-dependent CLA nitration by 30%, in concert with a 50% reduction in media NO<sub>2</sub><sup>-</sup> levels, revealing a contribution of <sup>•</sup>NO-derived species to CLA nitration (Fig. 3*d*).


**Nitration of CLA by Myeloperoxidase and Peroxynitrite**—During inflammation, neutrophil MPO catalyzes biomolecule nitration (33). The reaction of LA with MPO, NO<sub>2</sub><sup>-</sup>, and H<sub>2</sub>O<sub>2</sub> yielded oxidation products, with nitrated products undetectable under these conditions. Similar treatment of (9*Z*,11*E*)-CLA yielded 9- and 12-NO<sub>2</sub>-CLA and the further oxidized nitration products NO<sub>2</sub>-OH-OA (MRM 342.3/46) and NO<sub>2</sub>-oxo-OA (MRM 340.3/46) (Fig. 3*e*). MPO/H<sub>2</sub>O<sub>2</sub>/NO<sub>2</sub><sup>-</sup>-cata-

lyzed nitration of (9*Z*,11*E*)-CLA, even in the presence of high tyrosine concentrations, revealed that tyrosine does not compete with CLA for nitration. Moreover, the addition of a 50–400 M excess of tyrosine over CLA increased CLA nitration, most likely a consequence of reactions between tyrosyl and nitroalkenyl radical intermediates (Fig. 3*f*). This indicates that although LA is a very poor substrate, CLA is a preferential target for nitration by <sup>•</sup>NO<sub>2</sub>, even in the presence of other nitration-susceptible species.

The reaction of LA (1 μM) with ONOO<sup>-</sup> (0–20 μM) also gave no detectable nitrated species, whereas ONOO<sup>-</sup> induced a dose-dependent nitration of (9*Z*,11*E*)-CLA (Fig. 3*g*). The addition of ONOO<sup>-</sup> to reaction systems prior to lipid target, to allow for its decay to NO<sub>3</sub><sup>-</sup>, did not support CLA nitration (Fig. 3*g*). Notably, all biochemical conditions tested (mitochondria, plasma, cardiac tissue after focal I/R, activated RAW cells, acidic NO<sub>2</sub><sup>-</sup>, MPO/H<sub>2</sub>O<sub>2</sub>/NO<sub>2</sub><sup>-</sup>, ONOO<sup>-</sup>, and pure <sup>•</sup>NO<sub>2</sub> gas) yielded the same NO<sub>2</sub>-CLA regioisomers (supplemental Fig. 5). In addition to NO<sub>2</sub>-CLA, NO<sub>2</sub>-oxo-OA and NO<sub>2</sub>-OH-OA were also generated during CLA nitration reactions (Fig. 3 and Scheme 1), although no nitrated products were observed using its positional isomer LA as a substrate.

**Nitration of CLA by <sup>•</sup>NO<sub>2</sub> Gas and the Electrophilic Reactivity of NO<sub>2</sub>-CLA**—The electrophilic nitroalkene of NO<sub>2</sub>-FA mediates the signaling actions of these species through the post-translational protein modifications of cysteine and to a lesser extent histidine (15, 34). To probe NO<sub>2</sub>-CLA electrophilicity, reactivity toward β-ME was evaluated (26). NO<sub>2</sub>-CLA reacted rapidly, yielding products detected by the neutral loss of β-ME (78 atomic mass units) upon CID fragmentation (reverse Michael addition) to give NO<sub>2</sub>-CLA (MRM 402.4/324.2), NO<sub>2</sub>-oxo-OA (MRM 418.4/340.3), and [<sup>13</sup>C<sub>18</sub>]NO<sub>2</sub>-LA (MRM 420.4/342.2, Fig. 4*a*). Further structural characterization of the ion  $m/z$  340.3 revealed a nitroalkane with an α,β-unsaturated carbonyl that also conferred electrophilic character. No β-ME


## Fatty Acid Nitration in Vitro and in Vivo



**FIGURE 3. CLA nitration by mitochondria, activated RAW 264.7 macrophages, MPO, and ONOO<sup>-</sup>.** *a*, mitochondria (2 mg) were incubated in the presence of NO<sub>2</sub><sup>-</sup> (0.25–1.0 mM) and supplemented with various fatty acids (1 μM). Lipids were extracted, and NO<sub>2</sub>-FA was quantified by HPLC-MS/MS using [<sup>13</sup>C<sub>18</sub>]NO<sub>2</sub>-LA as internal standard. Results represent the mean ± S.D. (*n* = 3), \* indicates significantly different (*p* < 0.05) from control without fatty acid addition. *b*, NO<sub>2</sub>-CLA formation from endogenous CLA and the concomitant CLA consumption was quantified by HPLC-MS/MS in mitochondria (2 mg) incubated with NO<sub>2</sub><sup>-</sup> (1 mM) at pH 6 (*n* = 3). *c*, chromatogram showing formation of NO<sub>2</sub>-CLA by activated macrophages in the presence of CLA and internal standards ([<sup>15</sup>N]O<sub>2</sub>-CLA and [<sup>13</sup>C<sub>18</sub>]NO<sub>2</sub>-LA). *d*, incubation with the NOS inhibitor L-NAME decreased NO<sub>2</sub><sup>-</sup> (gray bars) and NO<sub>2</sub>-CLA (black bars) levels in media. *e*, CLA (10 μM) nitration induced by MPO/H<sub>2</sub>O<sub>2</sub>/NO<sub>2</sub> (30 min). Nitration (NO<sub>2</sub>-CLA, *m/z* 324.2) and oxidation (NO<sub>2</sub>-oxo-OA, *m/z* 340.3) products were quantified using [<sup>13</sup>C<sub>18</sub>]NO<sub>2</sub>-LA as internal standard. *f*, CLA (10 μM) nitration reactions by MPO were competed using increasing molar ratios of tyrosine (1–400 mol eq, Tyr/CLA). *g*, ONOO<sup>-</sup> induced formation of NO<sub>2</sub>-CLA (*m/z* 324.2) and NO<sub>2</sub>-oxo-OA (*m/z* 340.3). Results represent the mean of three independent experiments ± S.D. ND, not detected. *d*, \* and # are significantly different from CLA control (*p* < 0.05) in the absence of L-NAME (analysis of variance post hoc Tukey's test).

adducts were formed by NO<sub>2</sub>-OH-OA, as predicted from a structure that infers lack of electrophilicity (Scheme 1). The presence of an OH group at the ion *m/z* 342.2 was confirmed by Dess Martin-mediated oxidation to NO<sub>2</sub>-oxo-OA (*m/z* 340.2), now yielding a β-ME-reactive product (MRM 418.4/340.3) (Fig. 4*b*). Thus, although nitration of CLA generates electrophilic nitroalkenes and α-β-unsaturated ketone, NO<sub>2</sub>-OH-OA requires further oxidation to gain electrophilic reactivity.

CLA nitration occurs via <sup>•</sup>NO<sub>2</sub> addition (Scheme 1 and Figs. 1–3), a precept more directly tested by treating CLA and LA in solution with pure <sup>•</sup>NO<sub>2</sub> using air or N<sub>2</sub> as the carrier gas. HPLC-ESI-MS/MS quantification revealed that CLA yielded ~10<sup>5</sup> greater nitration products than LA (1.5 μM NO<sub>2</sub>-CLA




**SCHEME 1. Reaction mechanism of nitrogen dioxide-induced CLA nitration.** This pathway also depicts the formation of the hydroxy and keto containing NO<sub>2</sub>-FA derivatives that can be generated in the presence of oxygen. \* denotes electrophilic carbons.


versus 20 pM NO<sub>2</sub>-LA formed, see Fig. 4, *c* and *d*). Reactions performed in aerobic conditions produced further oxidized nitration products, including NO<sub>2</sub>-oxo-OA (*m/z* 340.3) and NO<sub>2</sub>-OH-OA (*m/z* 342.2) in addition to NO<sub>2</sub>-CLA (*m/z* 324.2). When reactions were conducted in N<sub>2</sub>-saturated conditions, the formation of NO<sub>2</sub>-CLA predominated (*m/z* 324, Fig. 4*c*). These data support the formation of a resonance-stabilized radical, upon addition of <sup>•</sup>NO<sub>2</sub> to the flanking carbons of the conjugated diene, that under aerobic conditions can further react with oxygen (Fig. 4*c* and Scheme 1).

**Detection of NO<sub>2</sub>-CLA in Healthy Human Plasma**—The nitration of CLA *in vitro* by diverse inflammatory-related mechanisms motivated clinical investigation of endogenous NO<sub>2</sub>-CLA. Analysis by HPLC-MS/MS revealed NO<sub>2</sub>-CLA in healthy human plasma, with identification confirmed by comparison with the synthetic [<sup>15</sup>N]O<sub>2</sub>-CLA internal standard (Fig. 5*a*). Endogenous levels of NO<sub>2</sub>-CLA in plasma ranged from 0.3 to 1.3 nM (average = 0.72 nM, median = 0.62 nM, *n* = 7, using [<sup>15</sup>N]O<sub>2</sub>-CLA as internal standard) (supplemental Fig. 6). Plasma NO<sub>2</sub>-CLA was reactive with β-ME. Upon β-ME addition, the NO<sub>2</sub>-CLA MRM elution profile (324.2/46) was lost (Fig. 5*a*, lower panel). Accurate mass determination, at resolution of 40,000 (<2 ppm), also confirmed the presence of NO<sub>2</sub>-CLA in plasma (Fig. 5*b*, upper panel). The nitrated CLA species (9-NO<sub>2</sub>-CLA and 12-NO<sub>2</sub>-CLA) were further confirmed by co-elution with synthetic standards, CID product ion fragmentation, and accurate mass determinations (supplemental Fig. 7, *a* and *b*). The *de novo* generation of NO<sub>2</sub>-CLA from plasma CLA was tested by adding 0.5 mM Na[<sup>15</sup>N]O<sub>2</sub> to plasma under acidic conditions for 30 min (Fig. 5*b*, lower panel). As a control for artifactual nitration during hexane extraction and post-extraction acidic conditions, hexadiene was added to compete for nitration. These controls and the inclusion of 10 μM Na[<sup>15</sup>N]O<sub>2</sub> (well above physiological level) plus 1 mM hexadiene in plasma showed no artifactual CLA nitration occurred during extraction procedures (supplemental Fig. 7*c*).

**Gastric Nitration of CLA**—The *ex vivo* acid-catalyzed nitration of CLA suggested that this reaction might occur *in vivo* in



**FIGURE 4. Nitrogen dioxide-mediated nitration of CLA and electrophilic reactivity of  $\text{NO}_2$ -CLA.** *a*, MS/MS chromatograms of  $\text{NO}_2$ -CLA,  $\text{NO}_2$ -OH-OA, and  $\text{NO}_2$ -oxo-OA pre- and post- $\beta$ -ME (1 mM) reaction. Chromatograms of  $\beta$ -ME adducted  $\text{NO}_2$ -FA followed the neutral loss of 78 atomic mass units ( $\beta$ -ME) ( $\beta$ -ME- $\text{NO}_2$ -CLA, 402.3/324.2;  $\beta$ -ME- $\text{NO}_2$ -oxo-OA, 418.3/340.3;  $\beta$ -ME- $^{13}\text{C}_{18}$   $\text{NO}_2$ -LA, 420.3/342.2) and show the characteristic shift in the elution time when compared with pre- $\beta$ -ME reaction  $\text{NO}_2$ -FA.  $\text{NO}_2$ -OH-OA does not display electrophilic reactivity. *b*, Dess Martin reaction (to oxidize hydroxy groups to ketones) of CLA nitration products shows specific oxidation only for  $\text{NO}_2$ -OH-OA to  $\text{NO}_2$ -oxo-OA and its subsequent gaining of  $\beta$ -ME reactivity. Product displays the same chromatographic profile as  $\text{NO}_2$ -oxo-OA shown in *a*. Oxygen tension modulates FA nitration product distribution during reaction with  $\text{NO}_2$ . CLA (100  $\mu\text{M}$ ) (*c*) or LA (100  $\mu\text{M}$ ) (*d*) nitration was induced by pure  $\text{NO}_2$  gas (5.6 ppm) during 60 min under hypoxia (black bars) and normoxia (white bars). Products were quantified by HPLC-MS/MS in the presence of  $^{13}\text{C}_{18}$   $\text{NO}_2$ -LA. ND, not detected. Results represent the mean of three independent experiments  $\pm$  S.D.




**FIGURE 5. Detection of  $\text{NO}_2$ -CLA in human plasma.** The presence of  $\text{NO}_2$ -CLA was identified and quantified using 9- $^{15}\text{N}$   $\text{O}_2$ -CLA and 12- $^{15}\text{N}$   $\text{O}_2$ -CLA as internal standards in plasma from seven healthy subjects. *a*, chromatograms show endogenous  $\text{NO}_2$ -CLA (324/46, middle panel) and internal standard  $^{15}\text{N}$   $\text{O}_2$ -CLA (325.3/47, upper panel). Confirmation of electrophilic reactivity of the endogenous  $\text{NO}_2$ -CLA was followed upon  $\beta$ -ME reaction (lower panel). *b*, accurate mass determinations (1 ppm level) of endogenous  $\text{NO}_2$ -CLA and plasma subjected to acidic nitration using  $\text{Na}^{15}\text{N}$   $\text{O}_2$  (0.5 mM) were determined for both 9- and 12- $\text{NO}_2$ -CLA.

acidic physiological environments such as the gastric compartment. Also,  $\text{NO}_2$  generation from  $\text{NO}_2^-$  occurs in the stomach (35). Mice, which have higher gastric pH values than humans, were fasted overnight, and pentagastrin was administered to mimic feeding-induced gastric acid secretion. Mice were then gavaged with CLA and  $\text{Na}^{15}\text{N}$   $\text{O}_2$  (100 nmol of each), resulting in an increase in  $\text{NO}_2$ -CLA content in stomach tissue that reached a maximum concentration 2 h after gavage ( $0.9 \pm 0.3$  nmol of  $\text{NO}_2$ -CLA/g of tissue) (Fig. 6*a*). When higher doses of CLA and  $\text{Na}^{15}\text{N}$   $\text{O}_2$  were given to nonfasting mice (100 and 10

$\mu\text{mol}$ , respectively),  $33 \pm 22$  nmol of  $\text{NO}_2$ -CLA/g of tissue was detected in the stomach. Increases in  $\text{NO}_2$ -CLA were also detected in the small intestine and colon at  $1.5 \pm 1.1$  and  $1.2 \pm 1.7$  nmol/g tissue, respectively. All treated animals showed detectable  $\text{NO}_2$ -CLA levels throughout the gastrointestinal tract, which was absent in control animals and animals gavaged with CLA alone. Upon administration of  $\text{NO}_2^-$  alone,  $\text{NO}_2$ -CLA ( $0.4 \pm 0.2$  nmol/g stomach) was detected, supporting the presence of significant native CLA and indicating that ingested  $\text{NO}_2^-$  levels are a factor in the digestive formation of  $\text{NO}_2$ -CLA.

## Fatty Acid Nitration in Vitro and in Vivo



**FIGURE 6. Gastric formation of [<sup>15</sup>N]O<sub>2</sub>-CLA modulates HO-1 expression in gut epithelium and levels in plasma, tissue, and urine.** *a*, fasted mice were injected with pentagastrin (5 mg/kg) 1 h prior to gavage with CLA (100 nmol) and Na[<sup>15</sup>N]O<sub>2</sub> (100 nmol). Lipids were extracted from stomach tissue and analyzed by HPLC-MS/MS. *b*, rats were fed CLA and Na[<sup>15</sup>N]O<sub>2</sub> via oral gavage once per day for 4 days (100 μmol each), and urine was collected over the final 24 h of treatment. Extracted lipids from urine and different tissues were analyzed by HPLC-MS/MS, revealing endogenous formation of labeled [<sup>15</sup>N]O<sub>2</sub>-CLA (*m/z* 325/47). *ND*, not detected. *c–h*, gastric generation of NO<sub>2</sub>-CLA stimulates expression of HO-1 in rat colon epithelium. Representative images of colon tissue from vehicle controls (*c* and *d*), CLA + NO<sub>2</sub><sup>-</sup> (*e* and *f*), and synthetic NO<sub>2</sub>-CLA treatment (*g* and *h*) are shown. The actin labeling (*green*) delineates the adventitia and the apical surface of epithelium. The nuclei are shown in *blue* (DAPI staining). *e* and *g* and *f* and *h* (high power magnification), there is intense HO-1 immunoreactivity (*red*) in the subapical cytoplasm of the epithelial cells (*yellow arrowheads*). This labeling is absent in the vehicle-treated control tissue (*c* and *d*). There is some discrete labeling within the lamina propria in both treated and control animals (*white arrows*), which corresponds to labeling that typically occurs in the macrophages and occasional dendritic cells found in this locale. *Bar*, 100 μm. *i*, NO<sub>2</sub>-CLA induces HO-1 expression in the mouse macrophage RAW 264.7 cells. Cells were incubated with [<sup>15</sup>N]O<sub>2</sub>-CLA (9- and 12-NO<sub>2</sub>-CLA isomer mixture), 9-NO<sub>2</sub>-CLA (specific isomer), bis-allylic NO<sub>2</sub>-LA, and control native fatty acids (CLA and LA) for 12 h. Results represent the mean of three independent experiments ± S.E.; \* and # are significantly different from CLA control (*p* < 0.05) and LA control (*p* < 0.05) (analysis of variance post hoc Tukey's test).

Electrophilic NO<sub>2</sub>-oxo-CLA was also detected throughout the gastrointestinal tract of CLA and NO<sub>2</sub><sup>-</sup>-gavaged mice.

To better evaluate the formation of NO<sub>2</sub>-CLA, rats were also treated with CLA and Na[<sup>15</sup>N]O<sub>2</sub>, allowing for greater fluid

volumes and tissue mass for the analysis of [<sup>15</sup>N]O<sub>2</sub>-CLA. The gastric formation, absorption, and distribution of [<sup>15</sup>N]O<sub>2</sub>-CLA after gavage with CLA and Na[<sup>15</sup>N]O<sub>2</sub> (100 μmol each) was detected in the stomach, intestine, colon, plasma, liver, and



urine (Fig. 6*b*). Structural characterization of [<sup>15</sup>N]O<sub>2</sub>-CLA in the tissues and urine collected from treated rats showed that these species displayed *m/z* and HPLC retention times identical to synthetic [<sup>15</sup>N]O<sub>2</sub>-CLA. Accurate mass determination (*m/z* 325.2150 for [<sup>15</sup>N]O<sub>2</sub>-CLA (theoretical 325.2151) and 324.2181 for NO<sub>2</sub>-CLA (theoretical 324.2180)) confirmed the atomic composition of these species at the 1 ppm level. The electrophilicity of these products was confirmed by β-ME reactivity (data not shown). These results support that dietary CLA and NO<sub>2</sub><sup>-</sup> content can modulate levels of NO<sub>2</sub>-CLA in tissues, plasma, and urine.

**Colonic Mucosal HO-1 Expression Is Induced by CLA and Nitrite Treatment of Rats**—The gastric formation of electrophilic NO<sub>2</sub>-CLA motivated the evaluation of whether endogenously generated electrophilic fatty acids can regulate gene expression in tissues. The expression of HO-1, a target gene for NO<sub>2</sub>-FA (15, 36), was analyzed by immunofluorescence microscopy. There was a significant increase in HO-1 expression in the cytosol of colonic epithelial cells of rats gavaged with CLA and NO<sub>2</sub><sup>-</sup> (Fig. 6, *e* and *f*) as well as synthetic NO<sub>2</sub>-CLA (Fig. 6, *g* and *h*), as compared with control rats fed vehicle (Fig. 6, *c* and *d*). Control studies showed that when no primary antibody was used, no staining or autofluorescence of tissue was detectable. No changes in basal HO-1 expression levels were observed in colonic epithelial cells of control rats that were gavaged with CLA or NO<sub>2</sub><sup>-</sup> individually and not as a binary mixture. Moreover, the expression of HO-1 was not up-regulated in the lamina propria immune cells (macrophages and dendritic cells) of the different treatment groups. To further confirm that NO<sub>2</sub>-CLA mediates signaling actions analogous to those reported for NO<sub>2</sub>-LA and NO<sub>2</sub>-OA (2, 15), HO-1 expression in RAW 264.7 macrophages was evaluated. Notably, Fig. 3, *c* and *d*, shows that RAW 264.7 macrophages mediate the nitration of CLA. In addition, [<sup>15</sup>N]O<sub>2</sub>-CLA (mixed 9- and 12-NO<sub>2</sub>-CLA regioisomers) induced a dose-dependent up-regulation of HO-1 expression comparable with that induced by NO<sub>2</sub>-LA and 9-NO<sub>2</sub>-CLA (Fig. 6*i*).

## DISCUSSION

The conjugated diene-containing fatty acid CLA is a preferential substrate for nitration reactions mediated by mitochondria, digestion, and macrophage activation and following metabolic stress such as focal cardiac I/R (supplemental Fig. 5) (17). Biochemical reaction systems reported herein reinforce that the increased rates of generation of reactive inflammatory mediators (partially reduced oxygen species and various oxides of nitrogen), metabolic acidosis, and low oxygen tensions all contribute to unsaturated lipid nitration.

The propensity of reactions yielding <sup>•</sup>NO<sub>2</sub> to induce the nitration of fatty acids is underscored by the lack of competition of tyrosine with CLA for nitration. The nitration of tyrosine occurs via a two-step mechanism, consisting of an initial hydrogen abstraction of the phenolic hydroxyl group, followed by radical rearrangement to a tyrosyl radical intermediate (Tyr<sup>•</sup>) that reacts with <sup>•</sup>NO<sub>2</sub> via radical-radical termination reaction (37). Herein, up to a 400-fold excess of tyrosine over CLA did not compete for the nitration of CLA by MPO/H<sub>2</sub>O<sub>2</sub>/NO<sub>2</sub><sup>-</sup>, and actually promoted CLA nitration. Other biological factors that

would influence relative extents of Tyr and CLA nitration under oxidative inflammatory conditions include the following: (a) the multiple independent and overlapping mechanisms leading to both lipid and Tyr<sup>•</sup> formation *in vivo* and (b) differences in the chemical reactivity and compartmentalization of tyrosine and conjugated diene-containing fatty acids.

Nitrated fatty acids have been detected both in animal tissues subjected to inflammatory conditions and endogenously in healthy human plasma and urine (25, 38). Initially, isobaric *cis* or *trans* bis-allylic 18:2 fatty acids were proposed to be the substrate for nitration reactions, based on the abundance and the acidity of the bis-allylic hydrogen. Present data now reveal that CLA regioisomers are the principal targets of fatty acid nitration *in vivo* and *in vitro*. CLA is unique in that it displays a reactivity toward <sup>•</sup>NO<sub>2</sub>-induced nitration several orders of magnitude greater than bis-allylic LA (Figs. 3 and 4, *c* and *d*). This preferential reactivity of <sup>•</sup>NO<sub>2</sub> toward CLA originates from the conjugated diene moiety, which in the gas phase is more reactive than simple monoalkenes by a factor of 10<sup>3</sup>–10<sup>4</sup> (39). In carbon tetrachloride, the conjugated diene 2,5-dimethyl-2,4-hexadiene is 10<sup>4</sup>–10<sup>6</sup> more reactive than monoalkenes (40), reinforcing that there will be a preferential reaction of <sup>•</sup>NO<sub>2</sub> with CLA rather than bis-allylic dienes, even when conjugated dienes are present in ~100-fold lower concentrations than other bis-allylic unsaturated fatty acids in plasma (41).

CLA nitration proceeds through the free radical addition of <sup>•</sup>NO<sub>2</sub> to one of the flanking alkenyl carbons, resulting in a radical product stabilized by electron resonance (Scheme 1). Thus, addition at the C-9 and C-12 positions prevails over additions at C-10 and C-11 and gives a delocalized allylic radical (42). Although consensus exists for the mechanism involved in the <sup>•</sup>NO<sub>2</sub> radical addition, the fate of the acyl chain radical formed upon <sup>•</sup>NO<sub>2</sub> addition is unclear. Possible reactions that could result in carbonyl radical reduction include a radical reaction between a second <sup>•</sup>NO<sub>2</sub> and the allyl radical intermediate through the nitrogen or oxygen atoms of <sup>•</sup>NO<sub>2</sub>, thereby yielding unstable dinitro or nitro-nitrito products, respectively. Nitrito functional groups would undergo rapid hydrolysis to yield the corresponding alcohol, with further elimination of water, resulting in a vinyl nitro product (43). Alternatively, hydrogen abstraction of the NO<sub>2</sub>-CLA radical intermediate by <sup>•</sup>NO<sub>2</sub> can generate HNO<sub>2</sub> and reform the corresponding vinyl nitro product. Dinitro and nitro-nitrito products have been reported as reaction products during the nitration of LA at pH < 3 (43), but no evidence for the formation of stable dinitro or nitro-nitrito CLA intermediates was apparent under the mild acidic conditions used herein (pH 5–7).

The presence of oxygen during fatty acid nitration promotes higher yields of NO<sub>2</sub>-OH and NO<sub>2</sub>-oxo products. The detection of NO<sub>2</sub>-OH-OA (*m/z* 342.2) and NO<sub>2</sub>-oxo-OA (*m/z* 340.3) further expands the potential product profiles of fatty acids nitrated by <sup>•</sup>NO<sub>2</sub>. In aggregate, these results indicate that conditions where the extent of <sup>•</sup>NO, NO<sub>2</sub><sup>-</sup>, and <sup>•</sup>NO<sub>2</sub> generation change along with different degrees of tissue acidosis and oxygenation, the yields of specific nitrated CLA products will be impacted. This in turn will influence downstream signaling actions due to the different electrophilic reactivities displayed by these compounds.

## Fatty Acid Nitration *In Vitro* and *In Vivo*

The biochemical mechanisms by which fatty acid nitration occurs are those that give rise to  $\cdot\text{NO}_2$  (44). These include exposure to  $\cdot\text{NO}_2$  gas, the  $\text{O}_2^-$ -derived inflammatory by-products ONOOH and nitrosoperoxocarbonate ( $\text{ONOOCO}_2^-$ ) (45), and heme protein-catalyzed oxidation of  $\text{NO}_2^-$  to  $\cdot\text{NO}_2$  (46). In activated macrophages and rodent hearts subjected to ischemia-reoxygenation, inhibition of nitric-oxide synthase (NOS) activity suppresses fatty acid nitration by  $\sim 50\%$  (Fig. 3*d*) (19, 47). Because  $\text{NO}_2^-$  is a product of  $\cdot\text{NO}$  autoxidation, the inhibition of fatty acid nitration by NOS inhibitors could be a consequence of the following: (a) suppressing the formation of  $\text{NO}_2^-$  or (b) limiting the reaction of  $\text{O}_2^-$  with  $\cdot\text{NO}$  and subsequent ONOO $^-$ -dependent  $\cdot\text{NO}_2$  generation.

The protonation of  $\text{NO}_2^-$  ( $\text{p}K_a$  3.4) to nitrous acid ( $\text{HNO}_2$ ) also yields  $\cdot\text{NO}_2$  from  $\text{N}_2\text{O}_3$  and  $\text{N}_2\text{O}_4$  homolysis (48). The acidic conditions of digestion induced the  $\text{NO}_2^-$ -dependent nitration of CLA, leading to increased levels of  $\text{NO}_2$ -CLA in gastrointestinal tract tissue. The administration of  $[\text{N}^{15}]\text{O}_2^-$  by gavage permitted differentiation from endogenous  $\text{NO}_2$ -CLA species. After gastric CLA nitration and absorption from the gut,  $[\text{N}^{15}]\text{O}_2$ -CLA was detected in plasma, liver, and urine. These observations are of relevance to other physiological compartments where pH levels are or can become sufficiently acidic to support  $\text{NO}_2^-$  protonation ( $\text{p}K_a$  3.4) to  $\text{HNO}_2$ . This includes phagolysosomes, actively respiring mitochondria, and tissues subjected to ischemic episodes or inflammation.

Electrophilic fatty acid derivatives react with nucleophilic amino acids of proteins via Michael addition, thereby altering protein structure and function (2). These modifications have typically been viewed as toxic, but recent data affirm that very low concentrations or rates of generation of reversibly reactive electrophiles mediate transient and functionally significant reactions with susceptible protein targets, eliciting a broad range of responses. The consideration of the endogenous generation, metabolism, and reactions of electrophilic  $\text{NO}_2$ -FA is of relevance because these species potentially limit inflammation via multiple mechanisms, including PPAR $\gamma$  activation, the inhibition of expression of pro-inflammatory NF- $\kappa$ B-regulated genes, and up-regulation of HO-1 and other phase 2 genes regulated by Keap1/Nrf2. Thus, in murine models of metabolic and inflammatory injury, fatty acid nitroalkene administration at nanomolar concentrations prevents restenosis after vessel injury (49), limits weight gain and loss of insulin sensitivity in murine models of metabolic syndrome (14), protects against ischemia-reperfusion injury (17, 47, 50), reduces plaque formation in a rodent model of atherosclerosis (51), and inhibits the onset of chemically induced inflammatory bowel disease (52).

There is a provocative convergence of the actions attributed to both the precursors ( $\text{NO}_2^-$  and CLA) and the products (fatty acid nitroalkenes), as these species induce positive metabolic responses and anti-inflammatory actions. Nitrite is an inorganic anion that is enriched in vegetables and both fresh and cured meats. It is also the product of nitrate ( $\text{NO}_3^-$ ) reduction by commensal bacterial nitrate reductases in saliva and the gut (53) and is a product of  $\cdot\text{NO}$  oxidation. Nitrite serves as an *in vivo* reservoir for  $\cdot\text{NO}$  generation, alters mitochondrial function (54), and manifests a broad array of anti-inflammatory actions in model systems (22). Similarly, the putative PPAR $\gamma/\alpha$

ligand activity and NF- $\kappa$ B inhibitory properties of CLA are proposed as the primary mechanisms of action accounting for its anti-cancer, anti-atherogenic, and immune regulatory effects (55). Considering that nitroalkene fatty acid derivatives are readily generated from CLA and that  $\text{NO}_2$ -FA are orders of magnitude more potent than native fatty acids in modulating similar transcriptional regulatory mechanisms of anti-inflammatory signaling (2, 24), Fig. 6 reveals that nitroalkenes can mediate the transduction of many of the salutary signaling actions noted for both  $\text{NO}_2^-$  and CLA.

In summary, conjugated dienes are a preferential target of nitration reactions during oxidative inflammatory conditions and digestion, leading to the formation of electrophilic products that act as potent transcriptional regulatory mediators. These fatty acid derivatives and their metabolites are detected in the plasma of healthy humans and are generated during digestion, metabolic stress, and inflammation.

*Acknowledgments*—We thank Edward Postlethwait, Giuseppe Squadrito, and Stacy Gelhaus for their collegial input.

## REFERENCES

1. Serhan, C. N., and Petasis, N. A. (2011) Resolvins and protectins in inflammation resolution. *Chem. Rev.* **111**, 5922–5943
2. Schopfer, F. J., Cipollina, C., and Freeman, B. A. (2011) Formation and signaling actions of electrophilic lipids. *Chem. Rev.* **111**, 5997–6021
3. Groeger, A. L., Cipollina, C., Cole, M. P., Woodcock, S. R., Bonacci, G., Rudolph, T. K., Rudolph, V., Freeman, B. A., and Schopfer, F. J. (2010) Cyclooxygenase-2 generates anti-inflammatory mediators from  $\omega$ -3 fatty acids. *Nat. Chem. Biol.* **6**, 433–441
4. Cui, T., Schopfer, F. J., Zhang, J., Chen, K., Ichikawa, T., Baker, P. R., Batthyany, C., Chacko, B. K., Feng, X., Patel, R. P., Agarwal, A., Freeman, B. A., and Chen, Y. E. (2006) Nitrated fatty acids. Endogenous anti-inflammatory signaling mediators. *J. Biol. Chem.* **281**, 35686–35698
5. Saravanan, P., Davidson, N. C., Schmidt, E. B., and Calder, P. C. (2010) Cardiovascular effects of marine  $\omega$ -3 fatty acids. *Lancet* **376**, 540–550
6. Turpeinen, A. M., Mutanen, M., Aro, A., Salminen, I., Basu, S., Palmquist, D. L., and Griinari, J. M. (2002) Bioconversion of vaccenic acid to conjugated linoleic acid in humans. *Am. J. Clin. Nutr.* **76**, 504–510
7. Lindsay, T., Walker, P. M., Mickle, D. A., and Romaschin, A. D. (1988) Measurement of hydroxy-conjugated dienes after ischemia-reperfusion in canine skeletal muscle. *Am. J. Physiol.* **254**, H578–H583
8. Huyser, E. S., Siegert, F. W., Sinnige, H. J., and Wynberg, H. (1966) Free-radical reactions of 2-*t*-butyl-1,3-butadiene and 2,3-di-*t*-butyl-1,3-butadiene. *J. Org. Chem.* **31**, 2437–2441
9. Adkins, Y., and Kelley, D. S. (2010) Mechanisms underlying the cardioprotective effects of  $\omega$ -3 polyunsaturated fatty acids. *J. Nutr. Biochem.* **21**, 781–792
10. Evans, N. P., Misyak, S. A., Schmelz, E. M., Guri, A. J., Hontecillas, R., and Bassaganya-Riera, J. (2010) Conjugated linoleic acid ameliorates inflammation-induced colorectal cancer in mice through activation of PPAR $\gamma$ . *J. Nutr.* **140**, 515–521
11. Bates, D. J., Smitherman, P. K., Townsend, A. J., King, S. B., and Morrow, C. S. (2011) Nitroalkene fatty acids mediate activation of Nrf2/ARE-dependent and PPAR $\gamma$ -dependent transcription by distinct signaling pathways and with significantly different potencies. *Biochemistry* **50**, 7765–7773
12. Nishida, M., Sawa, T., Kitajima, N., Ono, K., Inoue, H., Ihara, H., Motohashi, H., Yamamoto, M., Suematsu, M., Kurose, H., van der Vliet, A., Freeman, B. A., Shibata, T., Uchida, K., Kumagai, Y., and Akaike, T. (2012) Hydrogen sulfide anion regulates redox signaling via electrophile sulfhydration. *Nat. Chem. Biol.* **8**, 714–724
13. Kansanen, E., Jyrkkänen, H. K., Volger, O. L., Leinonen, H., Kivelä, A. M.,

- Häkkinen, S. K., Woodcock, S. R., Schopfer, F. J., Horrevoets, A. J., Ylä-Herttuala, S., Freeman, B. A., and Levonen, A. L. (2009) Nrf2-dependent and -independent responses to nitro-fatty acids in human endothelial cells. Identification of heat shock response as the major pathway activated by nitro-oleic acid. *J. Biol. Chem.* **284**, 33233–33241
14. Schopfer, F. J., Cole, M. P., Groeger, A. L., Chen, C. S., Khoo, N. K., Woodcock, S. R., Golin-Bisello, F., Motanya, U. N., Li, Y., Zhang, J., Garcia-Barrio, M. T., Rudolph, T. K., Rudolph, V., Bonacci, G., Baker, P. R., Xu, H. E., Batthyany, C. I., Chen, Y. E., Hallis, T. M., and Freeman, B. A. (2010) Covalent peroxisome proliferator-activated receptor  $\gamma$  adduction by nitro-fatty acids. Selective ligand activity and anti-diabetic signaling actions. *J. Biol. Chem.* **285**, 12321–12333
  15. Kansanen, E., Bonacci, G., Schopfer, F. J., Kuosmanen, S. M., Tong, K. I., Leinonen, H., Woodcock, S. R., Yamamoto, M., Carlberg, C., Ylä-Herttuala, S., Freeman, B. A., and Levonen, A. L. (2011) Electrophilic nitro-fatty acids activate NRF2 by a KEAP1 cysteine 151-independent mechanism. *J. Biol. Chem.* **286**, 14019–14027
  16. Lundberg, J. O., Carlström, M., Larsen, F. J., and Weitzberg, E. (2011) Roles of dietary inorganic nitrate in cardiovascular health and disease. *Cardiovasc. Res.* **89**, 525–532
  17. Rudolph, V., Rudolph, T. K., Schopfer, F. J., Bonacci, G., Woodcock, S. R., Cole, M. P., Baker, P. R., Ramani, R., and Freeman, B. A. (2010) Endogenous generation and protective effects of nitro-fatty acids in a murine model of focal cardiac ischaemia and reperfusion. *Cardiovasc. Res.* **85**, 155–166
  18. Baker, P. R., Lin, Y., Schopfer, F. J., Woodcock, S. R., Groeger, A. L., Batthyany, C., Sweeney, S., Long, M. H., Iles, K. E., Baker, L. M., Branchaud, B. P., Chen, Y. E., and Freeman, B. A. (2005) Fatty acid transduction of nitric oxide signaling. Multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferator-activated receptor ligands. *J. Biol. Chem.* **280**, 42464–42475
  19. Ferreira, A. M., Ferrari, M. I., Trostchansky, A., Batthyany, C., Souza, J. M., Alvarez, M. N., López, G. V., Baker, P. R., Schopfer, F. J., O'Donnell, V., Freeman, B. A., and Rubbo, H. (2009) Macrophage activation induces formation of the anti-inflammatory lipid cholesteryl-nitrolinoleate. *Biochem. J.* **417**, 223–234
  20. Dezfulian, C., Shiva, S., Alekseyenko, A., Pendyal, A., Beiser, D. G., Munasinghe, J. P., Anderson, S. A., Chesley, C. F., Vanden Hoek, T. L., and Gladwin, M. T. (2009) Nitrite therapy after cardiac arrest reduces reactive oxygen species generation, improves cardiac and neurological function, and enhances survival via reversible inhibition of mitochondrial complex I. *Circulation* **120**, 897–905
  21. Rudolph, V., and Freeman, B. A. (2009) Cardiovascular consequences when nitric oxide and lipid signaling converge. *Circ. Res.* **105**, 511–522
  22. Lundberg, J. O., Gladwin, M. T., Ahluwalia, A., Benjamin, N., Bryan, N. S., Butler, A., Cabrales, P., Fago, A., Feelisch, M., Ford, P. C., Freeman, B. A., Frenneaux, M., Friedman, J., Kelm, M., Kevil, C. G., Kim-Shapiro, D. B., Kozlov, A. V., Lancaster, J. R., Jr., Lefer, D. J., McColl, K., McCurry, K., Patel, R. P., Petersson, J., Rassaf, T., Reutov, V. P., Richter-Addo, G. B., Schechter, A., Shiva, S., Tsuchiya, K., van Faassen, E. E., Webb, A. J., Zuckerbraun, B. S., Zweier, J. L., and Weitzberg, E. (2009) Nitrate and nitrite in biology, nutrition, and therapeutics. *Nat. Chem. Biol.* **5**, 865–869
  23. Zulet, M. A., Marti, A., Parra, M. D., and Martínez, J. A. (2005) Inflammation and conjugated linoleic acid. Mechanisms of action and implications for human health. *J. Physiol. Biochem.* **61**, 483–494
  24. Schopfer, F. J., Lin, Y., Baker, P. R., Cui, T., Garcia-Barrio, M., Zhang, J., Chen, K., Chen, Y. E., and Freeman, B. A. (2005) Nitrolinoleic acid. An endogenous peroxisome proliferator-activated receptor  $\gamma$  ligand. *Proc. Natl. Acad. Sci. U.S.A.* **102**, 2340–2345
  25. Baker, P. R., Schopfer, F. J., Sweeney, S., and Freeman, B. A. (2004) Red cell membrane and plasma linoleic acid nitration products. Synthesis, clinical identification, and quantitation. *Proc. Natl. Acad. Sci. U.S.A.* **101**, 11577–11582
  26. Schopfer, F. J., Batthyany, C., Baker, P. R., Bonacci, G., Cole, M. P., Rudolph, V., Groeger, A. L., Rudolph, T. K., Nadtochiy, S., Brookes, P. S., and Freeman, B. A. (2009) Detection and quantification of protein adduction by electrophilic fatty acids. Mitochondrial generation of fatty acid nitroalkene derivatives. *Free Radic. Biol. Med.* **46**, 1250–1259
  27. Frezza, C., Cipolat, S., and Scorrano, L. (2007) Organelle isolation. Functional mitochondria from mouse liver, muscle, and cultured fibroblasts. *Nat. Protoc.* **2**, 287–295
  28. Dejam, A., Hunter, C. J., Tremonti, C., Pluta, R. M., Hon, Y. Y., Grimes, G., Partovi, K., Pelletier, M. M., Oldfield, E. H., Cannon, R. O., 3rd, Schechter, A. N., and Gladwin, M. T. (2007) Nitrite infusion in humans and nonhuman primates. Endocrine effects, pharmacokinetics, and tolerance formation. *Circulation* **116**, 1821–1831
  29. Dennis, S. C., Gevers, W., and Opie, L. H. (1991) Protons in ischemia. Where do they come from; where do they go to? *J. Mol. Cell Cardiol.* **23**, 1077–1086
  30. Bonacci, G., Ascuitto, E. K., Woodcock, S. R., Salvatore, S. R., Freeman, B. A., and Schopfer, F. J. (2011) Gas-phase fragmentation analysis of nitro-fatty acids. *J. Am. Soc. Mass Spectrom.* **22**, 1534–1551
  31. Trostchansky, A., Souza, J. M., Ferreira, A., Ferrari, M., Blanco, F., Trujillo, M., Castro, D., Cerecetto, H., Baker, P. R., O'Donnell, V. B., and Rubbo, H. (2007) Synthesis, isomer characterization, and anti-inflammatory properties of nitroarachidonate. *Biochemistry* **46**, 4645–4653
  32. Schopfer, F. J., Baker, P. R., and Freeman, B. A. (2003) NO-dependent protein nitration. A cell signaling event or an oxidative inflammatory response? *Trends Biochem. Sci.* **28**, 646–654
  33. Baldus, S., Eiserich, J. P., Mani, A., Castro, L., Figueroa, M., Chumley, P., Ma, W., Tousson, A., White, C. R., Bullard, D. C., Brennan, M. L., Lulis, A. J., Moore, K. P., and Freeman, B. A. (2001) Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. *J. Clin. Invest.* **108**, 1759–1770
  34. Batthyany, C., Schopfer, F. J., Baker, P. R., Durán, R., Baker, L. M., Huang, Y., Cerveñansky, C., Branchaud, B. P., and Freeman, B. A. (2006) Reversible post-translational modification of proteins by nitrated fatty acids *in vivo*. *J. Biol. Chem.* **281**, 20450–20463
  35. Pannala, A. S., Mani, A. R., Rice-Evans, C. A., and Moore, K. P. (2006) pH-dependent nitration of *para*-hydroxyphenylacetic acid in the stomach. *Free Radic. Biol. Med.* **41**, 896–901
  36. Wright, M. M., Kim, J., Hock, T. D., Leitinger, N., Freeman, B. A., and Agarwal, A. (2009) Human haem oxygenase-1 induction by nitro-linoleic acid is mediated by cAMP, AP-1, and E-box response element interactions. *Biochem. J.* **422**, 353–361
  37. Radi, R. (2004) Nitric oxide, oxidants, and protein tyrosine nitration. *Proc. Natl. Acad. Sci. U.S.A.* **101**, 4003–4008
  38. Lima, E. S., Di Mascio, P., Rubbo, H., and Abdalla, D. S. (2002) Characterization of linoleic acid nitration in human blood plasma by mass spectrometry. *Biochemistry* **41**, 10717–10722
  39. Atkinson, R., Aschmann, S. M., Winer, A. M., and Pitts, J. N., Jr. (1984) Gas phase reaction of NO<sub>2</sub> with alkenes and dialkenes. *Int. J. Chem. Kinet.* **16**, 697–706
  40. Giamalva, D. H., Kenion, G. B., Church, D. F., and Pryor, W. A. (1987) Rates and mechanisms of reaction of nitrogen dioxide with alkenes in solution. *J. Am. Chem. Soc.* **109**, 7059–7063
  41. Zlatanov, S. N., Laskaridis, K., and Sagredos, A. (2008) A conjugated linoleic acid content of human plasma. *Lipids Health Dis.* **7**, 34
  42. Claridge, R. P., Deeming, A. J., Paul, N., Tocher, D. A., and Ridd, J. H. (1998) The reactions of nitrogen dioxide with dienes. *J. Chem. Soc.* **1**, 3523–3528
  43. Napolitano, A., Camera, E., Picardo, M., and d'Ischia, M. (2000) Acid-promoted reactions of ethyl linoleate with nitrite ions. Formation and structural characterization of isomeric nitroalkane, nitrohydroxy, and novel 3-nitro-1,5-hexadiene and 1,5-dinitro-1,3-pentadiene products. *J. Org. Chem.* **65**, 4853–4860
  44. O'Donnell, V. B., Eiserich, J. P., Chumley, P. H., Jablonsky, M. J., Krishna, N. R., Kirk, M., Barnes, S., Darley-Usmar, V. M., and Freeman, B. A. (1999) Nitration of unsaturated fatty acids by nitric oxide-derived reactive nitrogen species peroxynitrite, nitrous acid, nitrogen dioxide, and nitronium ion. *Chem. Res. Toxicol.* **12**, 83–92
  45. Denicola, A., Freeman, B. A., Trujillo, M., and Radi, R. (1996) Peroxynitrite reaction with carbon dioxide/bicarbonate. Kinetics and influence on peroxynitrite-mediated oxidations. *Arch. Biochem. Biophys.* **333**, 49–58
  46. Eiserich, J. P., Hristova, M., Cross, C. E., Jones, A. D., Freeman, B. A., Halliwell, B., and van der Vliet, A. (1998) Formation of nitric oxide-derived

## Fatty Acid Nitration in Vitro and in Vivo

- inflammatory oxidants by myeloperoxidase in neutrophils. *Nature* **391**, 393–397
47. Nadtochiy, S. M., Baker, P. R., Freeman, B. A., and Brookes, P. S. (2009) Mitochondrial nitroalkene formation and mild uncoupling in ischaemic preconditioning. Implications for cardioprotection. *Cardiovasc. Res.* **82**, 333–340
48. Napolitano, A., Crescenzi, O., Camera, E., Giudicianni, I., Picardo, M., and d'Ischia, M. (2004) The acid-promoted reaction of ethyl linoleate with nitrite. New insights from <sup>15</sup>N-labeling and peculiar reactivity of a model skipped diene. *Tetrahedron* **58**, 5061–5067
49. Cole, M. P., Rudolph, T. K., Khoo, N. K., Motanya, U. N., Golin-Bisello, F., Wertz, J. W., Schopfer, F. J., Rudolph, V., Woodcock, S. R., Bolisetty, S., Ali, M. S., Zhang, J., Chen, Y. E., Agarwal, A., Freeman, B. A., and Bauer, P. M. (2009) Nitro-fatty acid inhibition of neointima formation after endoluminal vessel injury. *Circ. Res.* **105**, 965–972
50. Liu, H., Jia, Z., Soodvilai, S., Guan, G., Wang, M. H., Dong, Z., Symons, J. D., and Yang, T. (2008) Nitro-oleic acid protects the mouse kidney from ischemia and reperfusion injury. *Am. J. Physiol. Renal Physiol.* **295**, F942–F949
51. Rudolph, T. K., Rudolph, V., Edreira, M. M., Cole, M. P., Bonacci, G., Schopfer, F. J., Woodcock, S. R., Franek, A., Pekarova, M., Khoo, N. K., Hasty, A. H., Baldus, S., and Freeman, B. A. (2010) Nitro-fatty acids reduce atherosclerosis in apolipoprotein E-deficient mice. *Arterioscler. Thromb. Vasc. Biol.* **30**, 938–945
52. Borniquel, S., Jansson, E. A., Cole, M. P., Freeman, B. A., and Lundberg, J. O. (2010) Nitrated oleic acid up-regulates PPAR $\gamma$  and attenuates experimental inflammatory bowel disease. *Free Radic. Biol. Med.* **48**, 499–505
53. Lundberg, J. O., Weitzberg, E., and Gladwin, M. T. (2008) The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. *Nat. Rev. Drug. Discov.* **7**, 156–167
54. Shiva, S., and Gladwin, M. T. (2009) Nitrite mediates cytoprotection after ischemia/reperfusion by modulating mitochondrial function. *Basic Res. Cardiol.* **104**, 113–119
55. Reynolds, C. M., and Roche, H. M. (2010) Conjugated linoleic acid and inflammatory cell signalling. *Prostaglandins Leukot. Essent. Fatty Acids* **82**, 199–204